News Cocrystal Pharma, Inc.

Equities

COCP

US19188J4094

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.556 ^USD	-0.39%		+8.80%	-9.66%

Mar. 28	Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 04	Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	Mar. 28	AQ
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A	Mar. 19	AQ
Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates	Jan. 04	CI
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates	Jan. 04	AQ
Top Premarket Gainers	Dec. 07	MT
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A	Dec. 06	AQ
Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A	Dec. 06	CI
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	Nov. 29	AQ
Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast	Nov. 29	CI
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023	Nov. 27	AQ
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	Nov. 13	AQ
Cocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	Nov. 09	AQ
Cocrystal Pharma : Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 - Form 8-K	23-10-31	PU
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344	23-10-31	AQ
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus	23-09-28	AQ
Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus	23-09-28	CI
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference	23-09-05	AQ
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	23-08-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cocrystal Pharma, Inc.

Equities

COCP

US19188J4094

Summary

Filters